Ambulatory use of blinatumomab in paediatric patients with relapsed or refractory B-cell acute lymphoblastic leukaemia at a single centre in South Africa

Abstract

Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer, with B-ALL comprising approximately 85% of all cases. Despite a high cure rate, those with refractory disease and/or relapsed (R/R) B-ALL have an inferior overall survival. Blinatumomab, a novel therapy, is a bispecific cluster of differentiation (CD)19-directed CD3 T-cell engager that has proven efficacy in children with R/R B-ALL. It is administered as a 28-day infusion with associated prolonged hospital admissions. To date, there are few publications on its use in paediatric B-ALL, including its use in the outpatient setting.
Contribution: This case series offers additional context and understanding in this regard.